Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
- PMID: 38182673
- DOI: 10.1038/s41409-023-02181-3
Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
Conflict of interest statement
Competing interests. The authors declare no competing interests.
References
-
- Holtan SG, Pasquini M, Weisdorf DJ. Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014;124:363–73. https://doi.org/10.1182/blood-2014-01-514786 . - DOI - PubMed - PMC
-
- Ramachandran V, Kolli SS, Strowd LC. Review of graft-versus-host disease. Dermatol Clin 2019;37:569–82. https://doi.org/10.1016/j.det.2019.05.014 . - DOI - PubMed
-
- Cutler CS, Koreth J, Ritz J. Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017;129:22–9. https://doi.org/10.1182/blood-2016-08-686659 . - DOI - PubMed - PMC
-
- Zhang Y, Ruiz P. Solid organ transplant-associated acute graft-versus-host disease. Arch Pathol Lab Med. 2010;134:1220–4. https://doi.org/10.5858/2008-0679-RS.1 . - DOI - PubMed
-
- Choe H, Ferrara JLM. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). Expert Opin Ther Targets. 2021;25:761–71. https://doi.org/10.1080/14728222.2021.1992383 . - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical